The Metabolic,Vascular and Inflammatory effects of Conjugated Linoleic acid in patients with the Metabolic Syndrome. - NA
Phase 1
- Conditions
- METABOLIC SYNDROME
- Registration Number
- EUCTR2005-003197-17-GB
- Lead Sponsor
- Cardiff and Vale NHS Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with the Metabolic syndrome as defined by the NCEP ATP 3 criteria with atleast 3 of the following
1.Fasting plasma glucose > 5.6mmol/l
2.Serum Triglycerides > 1.7mmol/l
3.Serum HDL Cholesterol < 1.0mmol/l
4.Blood pressure >130/85
5.Abdominal obesity
Waist girth >102cms in males
> 88 cms in females
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
1.Patients with Diabetes
2.Patients on NSAIDs,Aspirin
3.pregnancy and Lactation
4.Acute Renal and liver disease
5.Acute illness.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine the effects of Conjugated linoleic acid on inflammation through RAGE expression in males and females with the metabolic syndrome.;Secondary Objective: To establish the effects of Conjugated linoleic acid on insulin sensitivity,Body mass index,Artery stiffness,endothelial and platelet function.;Primary end point(s): The effect of Conjugated linoleic acid on inflammation and RAGE expression.
- Secondary Outcome Measures
Name Time Method